Skip to main content

Table 1 Clinicopathological characteristics of SKCM patients

From: Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients

Characteristics FAHSU cohort (N = 46) GEO cohort (N = 93) TCGA cohort (N = 472)
N (%)
 Age
   ≤ 60 years 21 (45.6) 53 (56.9) 258 (54.7)
   > 60 years 25 (54.4) 40 (43.1) 214 (45.3)
 Gender
  Male 30 (65.2) 55 (59.1) 297 (61.9)
  Female 16 (34.8) 38 (40.9) 183 (38.1)
 Clark level
  I 6 (13.0) 13 (13.9) 6 (1.8)
  II 25 (54.3) 25 (26.8) 18 (5.5)
  III–IV 12 (26.1) 47 (50.7) 246(75.5)
  V 3 (6.6) 8 (8.6) 56 (17.2)
 Breslow depth(mm)
  ≤ 0.75 5 (10.9) 15 (16.1) 36 (10.2)
  0.76–1.50 28 (60.9) 30 (32.2) 65 (18.4)
  1.51–4.00 11 (23.9) 39 (41.9) 106 (30.0)
  > 4.00 2 (4.3) 9 (9.8) 146 (41.4)
 pT stage
  T1–T2 32 (69.6) 57 (61.3) 121 (32.7)
  T3–T4 14 (30.4) 36 (38.7) 249 (67.3)
 pN stage
  N0 46 (100) 93 (100) 236 (65.0)
  N1 0 (0) 0 (0) 75 (20.7)
  N2 0 (0) 0 (0) 52 (14.3)
 pM stage
  M0 46 (100) 93 (100) 424 (94.4)
 M1 0 (0) 0 (0) 25 (5.6)
 Pathologic stage
  I–II 46 (100) 93 (100) 233 (53.9)
  III–IV 0 (0) 0 (0) 199 (46.1)
 Persistent distant metastasis
  No 46 (100) 93 (100) 217 (46.1)
  Yes 0 (0) 0 (0) 254 (53.9)
  1. SKCM, Skin Cutaneous Melanoma
  2. FAHSU, The First Affiliated Hospital of Soochow University
  3. GEO, The Gene Expression Omnibus
  4. TCGA, The Cancer Genome Atlas